|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003191,
umls-concept:C0017262,
umls-concept:C0021760,
umls-concept:C0031715,
umls-concept:C0085857,
umls-concept:C0096069,
umls-concept:C0164371,
umls-concept:C0185117,
umls-concept:C0205314,
umls-concept:C0225369,
umls-concept:C0387583,
umls-concept:C0442797,
umls-concept:C0679622,
umls-concept:C1366876,
umls-concept:C1521840,
umls-concept:C1833235,
umls-concept:C2911684
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-6-14
|
|
pubmed:abstractText |
Aurothiomalate is a disease-modifying antirheumatic drug that suppresses inflammation and retards cartilage degradation and bone erosion in arthritis. The molecular mechanisms of action of aurothiomalate are not known in detail. MAPK pathways are major signaling pathways in inflammation that regulate the production of many inflammatory and destructive factors in arthritis. The purpose of the present study was to investigate the effects of aurothiomalate on the activity of p38 MAPK and on the expression of MAPK phosphatase 1 (MKP-1), cyclooxygenase 2 (COX-2), matrix metalloproteinase 3 (MMP-3), and interleukin-6 (IL-6) in immortalized murine H4 chondrocytes and in intact human and murine cartilage.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1529-0131
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1650-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20178133-Analysis of Variance,
pubmed-meshheading:20178133-Animals,
pubmed-meshheading:20178133-Antirheumatic Agents,
pubmed-meshheading:20178133-Blotting, Western,
pubmed-meshheading:20178133-Cartilage, Articular,
pubmed-meshheading:20178133-Cells, Cultured,
pubmed-meshheading:20178133-Chondrocytes,
pubmed-meshheading:20178133-Cyclooxygenase 2,
pubmed-meshheading:20178133-Dual Specificity Phosphatase 1,
pubmed-meshheading:20178133-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:20178133-Female,
pubmed-meshheading:20178133-Gene Expression Regulation,
pubmed-meshheading:20178133-Gold Sodium Thiomalate,
pubmed-meshheading:20178133-Humans,
pubmed-meshheading:20178133-Interleukin-6,
pubmed-meshheading:20178133-Matrix Metalloproteinase 3,
pubmed-meshheading:20178133-Mice,
pubmed-meshheading:20178133-Mice, Transgenic,
pubmed-meshheading:20178133-Phosphorylation,
pubmed-meshheading:20178133-RNA, Messenger,
pubmed-meshheading:20178133-RNA Interference,
pubmed-meshheading:20178133-Radioimmunoassay,
pubmed-meshheading:20178133-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20178133-p38 Mitogen-Activated Protein Kinases
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs.
|
|
pubmed:affiliation |
The Immunopharmacology Research Group, University of Tampere Medical School and Tampere University Hospital, Tampere, Finland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
